Roux-en-Y gastric bypass achieves substantial resolution of migraine headache in the severely obese: 9-year experience in 81 patients.

BACKGROUND: Although migraine headache (MH) is more severe in the obese, the risk of developing MH in the obese population is controversial. The effect of surgical weight loss on morbidly obese patients with MH provides a unique opportunity to evaluate this potential association. METHODS: We analyzed the data from 702 morbidly obese patients who underwent Roux-en-Y gastric bypass (RYGB) from 2000 to 2009. We identified patients with physician-diagnosed MH taking antimigraine medication. RESULTS: The data are presented as the mean ± SEM, with the range in parentheses. Of the 102 patients with preoperative MH, 21 were excluded because they had <12-month follow-up data and 81 were followed up for 38.6 ± 3 months (range 12-123). Of the 81 patients, 90% were women. Their body mass index was 48 ± 1 kg/m(2) (range 37-85), and their age was 40 ± 1 years (range 18-62). After surgical weight loss, clinical improvement in MH was seen in 89% of patients within 5.6 ± .9 months (range 1-36; P < .01, chi-square test), with 57 reporting total resolution and 15 reporting partial resolution (9 experienced no change). Using logistic regression analysis, we showed that the improvement in MH after RYGB was independent of the improvement in migraine-associated co-morbidities, such as sleep apnea, menstrual dysfunction, depression, and anxiety. We also compared patients who developed MH after obesity onset with those who had MH before obesity. The MH after obesity onset group included 51 patients, of whom 48 showed clinical improvement (41 complete, 7 partial, and 3 no improvement). The MH before obesity group included 24 patients, of whom 18 showed clinical improvement (11 complete, 7 partial, and 6 no improvement). The MH after obesity group showed a greater rate of complete resolution of MH after RYGB than did the MH before obesity group (P < .01; chi-square test). CONCLUSIONS: Weight loss after RYGB substantially resolves MH, especially when obesity onset precedes MH onset. It remains to be determined whether RYGB-induced endocrine alterations or a reduction in adipokine burden contribute to migraine improvement.

Roux-en-Y gastric bypass ameliorates polycystic ovary syndrome and dramatically improves conception rates: a 9-year analysis.

BACKGROUND: Polycystic ovary syndrome (PCOS) is a common cause of infertility, especially in the morbidly obese. We evaluated the long-term effects of Roux-en-Y gastric bypass on PCOS and infertility. METHODS: A total of 566 morbidly obese women underwent Roux-en-Y gastric bypass from 2000 to 2009. A total of 31 patients (5.5%) had a history of PCOS. Of the 31 patients, 6 were postmenopausal and 5 lost to follow-up and were excluded. Telephone interviews were conducted with the 20 eligible patients. RESULTS: The mean age and body mass index was 32 ± 5.8 years (range 22-42) and 52.8 ± 9.08 kg/m(2) (range 37-76) before surgery. All 20 patients had ≥ 2 of 3 diagnostic criteria for PCOS, including clinical or biochemical evidence of hyperandrogenism, anovulation, or polycystic ovaries. Of these, 85% had oligomenorrhea, 70% had hirsutism, and 45% had type 2 diabetes mellitus with medication. Before surgery, 8 patients conceived with or without hormonal treatment, 2 did not desire pregnancy, and 10 did not conceive. The mean follow-up was 46.7 months. After surgical weight loss, menstruation was corrected in 82%, hirsutism had resolved in 29%, and 77.8% of those with diabetes had complete remission. Of the 10 patients who did not conceive before surgery, 4 no longer desired pregnancy, and the remaining 6 patients had become pregnant within 3 years of surgery-5 without any hormonal treatment and 1 with in utero insemination. CONCLUSION: Surgical weight loss after Roux-en-Y gastric bypass achieves excellent amelioration of PCOS manifestations and the postoperative conception rate in infertile PCOS subjects desiring pregnancy was 100%.

Resolution of hyperlipidemia follows surgical weight loss in patients undergoing Roux-en-Y gastric bypass surgery: a 6-year analysis of data.

BACKGROUND: Hyperlipidemia is a known risk factor for the development of atherosclerosis and coronary artery disease in morbidly obese individuals. The aim of our study was to review the trends in the serum lipid profiles of patients undergoing Roux-en-Y gastric bypass at our institution. METHODS: A retrospective 6-year analysis of data of patients undergoing Roux-en-Y gastric bypass was performed. The indicators of resolution of hyperlipidemia were reviewed for 6 months and then annually for 6 consecutive years. Hyperlipidemia was defined according to the American Heart Association and National Cholesterol Education Program Adult Treatment Panel III guidelines. The changes in the lipid profile of the patients with subnormal levels of high-density lipoprotein (HDL) cholesterol and total cholesterol/HDL cholesterol risk ratio were also examined. RESULTS: A total of 94 patients were diagnosed with hyperlipidemia, of whom 23 were receiving clinical treatment. The mean patient age was 39 ± 9 years, and the mean body mass index was 50 ± 9.6 kg/m(2), with a female predominance. The mean baseline serum levels were as follows: total cholesterol 220 ± 42.2 mg/dL, triglycerides 212 ± 123.5 mg/dL, low-density lipoprotein cholesterol 135 ± 34.2 mg/dL, and HDL cholesterol 51 ± 12 mg/dL. The optimization of serum total cholesterol, triglycerides, and low-density lipoprotein cholesterol profiles was seen in all patients within 6 months after surgery. The HDL cholesterol levels improved more slowly, reaching desirable levels within 12 months after surgery. All patients taking lipid-lowering agents no longer required the medication at the end of the study period. CONCLUSION: Roux-en-Y gastric bypass provides an effective remission of hyperlipidemia in morbidly obese patients, with most patients no longer requiring lipid-lowering agents within 6 months after surgery. The improvement in overall lipid profiles continued during follow-up after surgery.